Exelixis

Exelixis

Yahoo Finance • 21 days ago

Exelixis Announces STELLAR-303 Trial Results For Zanzalintinib Combination

(RTTNews) - Exelixis, Inc. (EXEL) on Monday reported final analysis results from the phase 3 STELLAR-303 trial evaluating zanzalintinib in combination with Roche's Tecentriq versus regorafenib in previously treated non-microsatellite insta... Full story

Yahoo Finance • last month

What to Know About This Fund's $5.4 Million Ultragenyx Purchase as Shares Slip 30% in One Year

Key Points Krensavage bought 241,245 Ultragenyx Pharmaceutical shares last quarter. The quarter-end position value increased by $4.75 million, reflecting both trading and share price changes. The trade represented a roughly 2% increase in... Full story

Yahoo Finance • last month

Exelixis, Inc. (EXEL): Renaissance Technologies Likes This Stock

We just covered the 12 Best Stocks to Invest In According to Jim Simons’ Renaissance Technologies and Exelixis, Inc. (NASDAQ:EXEL) ranks 7th on this list. Exelixis, Inc. (NASDAQ:EXEL) is another long-term holding in the 13F portfolio of R... Full story

Yahoo Finance • 2 months ago

Assessing Exelixis (EXEL) Valuation After Merck Zanzalintinib Keytruda Colorectal Cancer Collaboration

Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide. Exelixis (EXEL) is back in the spotlight after announcing a clinical development collaboration wit... Full story

Yahoo Finance • 2 months ago

Exelixis outlines December PDUFA timeline for ZANZA CRC filing while adding $750M buyback authorization

Earnings Call Insights: Exelixis (EXEL) Q1 2026 MANAGEMENT VIEW * Michael Morrissey (CEO, President & Director) said the company’s strategy is “to build a multi-franchise business in solid tumor oncology focused on GU and GI histologie... Full story

Yahoo Finance • 2 months ago

Pancreatic Neuroendocrine Tumors Market Research Report 2025-2035, Competitive Analysis of Key Players - Novartis, Pfizer, Exelixis, Merck, Ipsen Pharma, and Takeda Pharma

Company Logo The global pancreatic neuroendocrine tumors (PNETs) market is experiencing significant growth driven by rising incidence rates, advances in diagnostic imaging, and expanding therapeutic options. PNETs, rare tumors originating... Full story

Yahoo Finance • 3 months ago

Why Dow Jones Stock Merck Skidded 4% — And Boosted A Key Rival

Merck stock skidded Tuesday — while also buoying Exelixis — after the Dow Jones pharma outlet said a triple approach to kidney cancer failed. Continue Reading... Full story

Yahoo Finance • 3 months ago

Notable healthcare headlines for the week: Apellis, Centessa, and UnitedHealth in focus

Wall Street’s major market averages ended mixed on Thursday as markets assessed President Donald Trump’s address to the nation and the latest developments in the Middle East conflict. The tech-focused Nasdaq Composite finished +0.1%. At t... Full story

Yahoo Finance • 3 months ago

Advanced Renal Cell Carcinoma Treatment Market to Grow by $3.1 Billion During 2026-2030: Global Industry Assessment Featuring Pfizer, Merck & Co., Bristol-Myers Squibb, AstraZeneca, Novartis and More

Company Logo Advanced Renal Cell Carcinoma Treatment MarketAdvanced Renal Cell Carcinoma Treatment Market·GlobeNewswire Inc. Dublin, April 01, 2026 (GLOBE NEWSWIRE) -- The "Advanced Renal Cell Carcinoma Treatment Market Report 2026" has... Full story

Yahoo Finance • 3 months ago

Renal Cell Carcinoma Market Report 2026-2030 & 2035: Increasing Immunotherapy and Precision Oncology Programs Drives Market Expansion, Reaching USD 6.09 Billion by 2030

Dublin, April 01, 2026 (GLOBE NEWSWIRE) -- The "Renal Cell Carcinoma Market Report 2026" has been added to ResearchAndMarkets.com's offering. The report provides a comprehensive analysis, depicting global market size, regional shares,... Full story

Yahoo Finance • 3 months ago

Kidney Cancer Drugs Market to Grow by $2 Billion During 2026-2030: Pfizer, Novartis, Exelixis, Roche, Bristol Myers Squibb Company, and Bayer Lead the Industry

Company Logo Kidney Cancer Drugs MarketKidney Cancer Drugs Market·GlobeNewswire Inc. Dublin, March 31, 2026 (GLOBE NEWSWIRE) -- The "Kidney Cancer Drugs Market Report 2026" has been added to ResearchAndMarkets.com's offering. The globa... Full story

Yahoo Finance • 3 months ago

Recurrent Head and Neck Cancer Squamous Cell Carcinoma Markets and Competition Outlook 2026-2030: Personalized Medicine Drives Revenue Growth, Reaching $4.61 Billion by 2030

Dublin, March 30, 2026 (GLOBE NEWSWIRE) -- The "Recurrent Head and Neck Cancer Squamous Cell Carcinoma Market Report 2026" has been added to ResearchAndMarkets.com's offering. The report offers comprehensive insights on market size, reg... Full story

Yahoo Finance • 4 months ago

RBC Capital Lowers Exelixis (EXEL) Price Target to $43

Exelixis, Inc. (NASDAQ:EXEL) is one of the 15 Set-It-and-Forget-It Stocks to Buy in 2026.RBC Capital Lowers Exelixis (EXEL) Price Target to $43 On March 2, 2026, Exelixis, Inc. (NASDAQ:EXEL) saw its price target from RBC Capital lowered f... Full story

Yahoo Finance • 5 months ago

Here’s What Analysts Think About Arcus Biosciences (RCUS)

Arcus Biosciences, Inc. (NYSE:RCUS) is one of the best immunotherapy stocks to buy according to hedge funds. On February 12, Arcus Biosciences, Inc. (NYSE:RCUS) was downgraded to Equal Weight from Overweight at Wells Fargo, with the firm b... Full story

Yahoo Finance • 5 months ago

Biogen Announces Board Chair Transition

CAMBRIDGE, Mass., Feb. 11, 2026 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced that the Board of Directors has elected Dr. Maria C. Freire as Chair of the Board of Directors, effective immediately following the Company’s... Full story

Yahoo Finance • 5 months ago

MRNA Down Nearly 10% as FDA Refuses to Review Influenza Vaccine BLA

Moderna MRNA shares plunged around 10% in after-hours trading following the announcement that the FDA’s Center for Biologics Evaluation and Research (CBER) has issued a Refusal-to-File (RTF) letter for the biologics license application (BL... Full story

Yahoo Finance • 5 months ago

Exelixis outlines growth strategy as CABOMETYX franchise hits $2.12B, eyes 2026 zanzalintinib launch

Earnings Call Insights: Exelixis, Inc. (EXEL) Q4 2025 MANAGEMENT VIEW * CEO Michael Morrissey described 2025 as a “transformational year” with “strong growth across all components of our business,” reaffirming a “singular focus to buil... Full story

Yahoo Finance • 5 months ago

Why Exelixis (EXEL) is One of the Best Healthcare Stocks Under $50 to Invest In

Exelixis, Inc. (NASDAQ:EXEL) is one of the best healthcare stocks under $50 to invest in. On February 4, Barclays revised the price target on Exelixis, Inc. (NASDAQ:EXEL) to $44 from $41 and maintained an Equal Weight rating on the shares,... Full story

Yahoo Finance • 6 months ago

Noteworthy ETF Inflows: XBI, FOLD, MRNA, EXEL

Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the SPDR S&P Biotech ETF (Symbol: XBI) where we have detected an approximate $218.7 million dollar inflow -- that... Full story

Yahoo Finance • 7 months ago

Strategic Pharma Collaborations Propel RCC Market Growth

Company Logo The global advanced renal cell carcinoma (RCC) market is experiencing rapid growth driven by innovative treatment approaches, rising disease awareness, and an expanding patient base. Key factors include the adoption of target... Full story